Long-term efficacy and safety of addition of carboplatin with or without veliparib to standard neoadjuvant chemotherapy in triple-negative breast cancer: 4-year follow-up data from BrighTNess, a randomized phase 3 trial

Publikation

Long-term efficacy and safety of addition of carboplatin with or without veliparib to standard neoadjuvant chemotherapy in triple-negative breast cancer: 4-year follow-up data from BrighTNess, a randomized phase 3 trial

Wissenschaftlicher Artikel/Review - 27.01.2022

Geyer C E, Symmans W F, Rastogi P, Sohn J, Young R, Wright G S, Harkness C, McIntyre K, Yardley D, Dunbar M, Metzger O, Ponce Lorenzo J, Sikov W M, Huober Jens, Rugo H S, Wolmark N, O'Shaughnessy J, Maag D, Untch M, Golshan M, Loibl S

Long-term efficacy and safety of addition of carboplatin with or without veliparib to standard neoadjuvant chemotherapy in triple-negative breast cancer: 4-year follow-up data from BrighTNess, a randomized phase 3 trial

Loibl, S